Greenwich LifeSciences Inc. GLSI
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Greenwich LifeSciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies targeting breast cancer and other HER2/neu-expressing cancers. Its lead product candidate, GP2, is a nine-amino acid peptide derived from the HER2/neu protein, combined with GM-CSF to form GLSI-1…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees4
TickerGLSI
Statistics
Market Cap$359.0M
Revenue (TTM)$0
Net Income-$19.4M
Net Margin—
EPS$-1.43
P/E-16.01
P/S—
P/B64.15
EV/EBITDA-14.02
ROE-676.7%
Dividend Yield—
Price$24.48
Data: Twelve Data · Revenue = mcap / P/S